Managed Care, Oncology, and Telehealth in the Era of COVID-19.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 46
- Publication type:
- Article
Works matching IS 21534888 AND DT 2020 AND VI 11 AND IP 4
Results: 35
1
2
Comprehensive Cancer Centers and Integrated Delivery Networks.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 45
- Publication type:
- Article
3
How COVID-19 Is Affecting Patient Advocacy Groups: Financial Need Increasing.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 44
- Publication type:
- Article
4
Long-Term Data Support Use of Acalabrutinib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 42
- By:
- Publication type:
- Article
5
CAR T-Cell Therapy Shows Highly Durable Remissions in CLL and B-Cell Lymphoma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 41
- By:
- Publication type:
- Article
6
Axicabtagene Ciloleucel Induces Durable Responses in Advanced Follicular and Marginal-Zone Lymphoma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 40
- By:
- Publication type:
- Article
7
Adjuvant Atezolizumab Did Not Show Disease-Free Survival Benefit in High-Risk Urothelial Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 37
- By:
- Publication type:
- Article
8
Maintenance Avelumab New Standard of Care for Advanced Bladder Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 37
- By:
- Publication type:
- Article
9
Nivolumab plus Ipilimumab May Be a New First-Line Option for Patients with MSI-H or dMMR Metastatic Colorectal Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 36
- By:
- Publication type:
- Article
10
Pembrolizumab Doubles Progression-Free Survival in Subset of Patients with Metastatic Colorectal Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 35
- By:
- Publication type:
- Article
11
CAR T-Cell Therapy Shows Deep, Durable Responses in Relapsed or Refractory Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 34
- By:
- Publication type:
- Article
12
Pembrolizumab Added to First-Line Chemotherapy Improves Progression-Free Survival in Metastatic TNBC.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 32
- By:
- Publication type:
- Article
13
No Survival Benefit with Surgery and Radiation Added to Systemic Therapy in Patients with Newly Diagnosed Stage IV Breast Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 30
- By:
- Publication type:
- Article
14
Early Phase 2 Data Promising for Latetium-177 PSMA-617 in Metastatic Prostate Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 29
- By:
- Publication type:
- Article
15
Cabozantinib plus Atezolizumab Combination Shows Meaningful Activity in Metastatic Prostate Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 28
- By:
- Publication type:
- Article
16
Opdivo plus Yervoy and Limited Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 27
- Publication type:
- Article
17
Tecentriq plus Avastin Combination Approved for First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 26
- Publication type:
- Article
18
Cyramza plus Tarceva Approved for First-Line Treatment of Metastatic NSCLC with EGFR Mutation.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 24
- Publication type:
- Article
19
Opdivo Now Approved for Advanced Esophageal Squamous-Cell Carcinoma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 22
- Publication type:
- Article
20
Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 20
- Publication type:
- Article
21
Inqovi First Oral Hypomethylating Agent Approved for Intermediateor High-Risk Myelodysplastic Syndromes.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 20
- Publication type:
- Article
22
Olaparib Extends Survival by >1 Year in Patients with Ovarian Cancer and BRCA Mutation, Ushering in Personalized Medicine in This Malignancy.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 19
- By:
- Publication type:
- Article
23
The WEE1 Inhibitor Adavosertib Displays Promising Clinical Activity in Uterine Serous Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 18
- By:
- Publication type:
- Article
24
Intratumoral Injection of Cisplatin and Vinblastine, with or without Pembrolizumab, Improves Intracellular Transport in Patients with Advanced Solid Tumors.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 17
- By:
- Publication type:
- Article
25
Tumor-Infiltrating Lymphocyte Therapy Induces Responses Across Wide Range of Patients with Advanced Melanoma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 17
- By:
- Publication type:
- Article
26
Capmatinib Shows Activity in MET-Amplified Non-Small-Cell Lung Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 11
- By:
- Publication type:
- Article
27
Durvalumab plus Chemotherapy New Standard of Care for Extensive-Stage Small-Cell Lung Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 10
- By:
- Publication type:
- Article
28
The Value of Some Cancer Drugs Changes Substantially After Their Approval.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 8
- Publication type:
- Article
29
Germline Analysis Has Actionable Value in Selecting Targetable Treatments for Patients with Advanced Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 8
- By:
- Publication type:
- Article
30
Cemiplimab Cost-Effective for Advanced Cutaneous Squamous-Cell Carcinoma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 7
- By:
- Publication type:
- Article
31
Clinical Decision Support Helps Compliance with Evidence-Based Pathways.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 6
- By:
- Publication type:
- Article
32
Adjuvant Osimertinib a Practice-Changing Treatment in Early-Stage NSCLC with EGFR Mutation.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 1
- By:
- Publication type:
- Article
33
Oral Relugolix Equals Standard ADT, Slashes Cardiac Events in Patients with Advanced Prostate Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 1
- By:
- Publication type:
- Article
34
Cancer Drugs Show Promise as Potential Treatment for COVID-19.
- Published in:
- 2020
- Publication type:
- Proceeding
35
ASCO 2020 Presidential Address: Accelerating Progress, Prioritizing Diversity.
- Published in:
- 2020
- By:
- Publication type:
- Proceeding